Celgene Corporation Company Profile (NASDAQ:CELG)

About Celgene Corporation (NASDAQ:CELG)

Celgene Corporation logoCelgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Its commercial-stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier. The Company is also evaluating AG-221 (enasidenib) in combination with VIDAZA in newly diagnosed acute myeloid leukemia with isocitrate dehydrogenase-2 mutations.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:CELG
  • CUSIP: 15102010
  • Web: www.celgene.com
Capitalization:
  • Market Cap: $98.55565 billion
  • Outstanding Shares: 780,824,000
Average Prices:
  • 50 Day Moving Avg: $119.20
  • 200 Day Moving Avg: $119.73
  • 52 Week Range: $94.42 - $133.71
P/E:
  • Trailing P/E Ratio: 50.4980
  • Foreward P/E Ratio: 16.16
  • P/E Growth: 0.8400
Sales & Book Value:
  • Annual Revenue: $11.68 billion
  • Price / Sales: 8.88
  • Book Value: $9.79 per share
  • Price / Book: 13.57
Profitability:
  • EBIDTA: $4.11 billion
  • Net Margins: 18.32%
  • Return on Equity: 70.94%
  • Return on Assets: 16.37%
Debt:
  • Debt-to-Equity Ratio: 1.80%
  • Current Ratio: 4.42%
  • Quick Ratio: 4.23%
Misc:
  • Average Volume: 3.55 million shs.
  • Beta: 1.82
  • Short Ratio: 2
 

Frequently Asked Questions for Celgene Corporation (NASDAQ:CELG)

What is Celgene Corporation's stock symbol?

Celgene Corporation trades on the NASDAQ under the ticker symbol "CELG."

When did Celgene Corporation's stock split? How did Celgene Corporation's stock split work?

Shares of Celgene Corporation split on the morning of Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly issued shares were payable to shareholders after the market closes on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene Corporation stock prior to the split would have 200 shares after the split.

How were Celgene Corporation's earnings last quarter?

Celgene Corporation (NASDAQ:CELG) posted its quarterly earnings results on Thursday, April, 27th. The company reported $1.68 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.47 by $0.21. The business had revenue of $2.96 billion for the quarter, compared to analysts' expectations of $3.04 billion. Celgene Corporation had a net margin of 18.32% and a return on equity of 70.94%. Celgene Corporation's revenue was up 17.8% on a year-over-year basis. During the same period last year, the business posted $1.32 EPS. View Celgene Corporation's Earnings History.

When will Celgene Corporation make its next earnings announcement?

Celgene Corporation is scheduled to release their next quarterly earnings announcement on Wednesday, July, 26th 2017. View Earnings Estimates for Celgene Corporation.

What guidance has Celgene Corporation issued on next quarter's earnings?

Celgene Corporation issued an update on its FY17 earnings guidance on Thursday, April, 27th. The company provided earnings per share guidance of $7.15-7.30 for the period, compared to the Thomson Reuters consensus estimate of $7.21. The company issued revenue guidance of $13.0-13.4 billion, compared to the consensus revenue estimate of $13.26 billion.

Where is Celgene Corporation's stock going? Where will Celgene Corporation's stock price be in 2017?

25 equities research analysts have issued twelve-month price objectives for Celgene Corporation's shares. Their forecasts range from $98.00 to $162.00. On average, they anticipate Celgene Corporation's stock price to reach $140.24 in the next year. View Analyst Ratings for Celgene Corporation.

What are analysts saying about Celgene Corporation stock?

Here are some recent quotes from research analysts about Celgene Corporation stock:

  • 1. Cann analysts commented, "The 2017 American Society of Clinical Oncology Meeting provided a venue for data presentations for a number of Celgene’s partnered programs, including enasidenib, BMCA CAR-T and JARCAR 017. Celgene had data on its wholly owned products, Revlimid and Abraxane." (6/7/2017)
  • 2. According to Zacks Investment Research, "Celgene’s key growth driver, Revlimid, continues to drive revenues at the company. Revlimid continued to outperform on the back of market share gains and increased duration. Other key products – Pomalyst/Imnovid, Abraxane and Otezla – also performed well. Both Otezla and Pomalyst achieved blockbuster status in 2016 recording over $1 billion in sales. Meanwhile, Celgene continues to progress with its label expansion efforts and pipeline development. Label expansion of approved drugs would boost its revenues. Sales of Revlimid are expected to maintain momentum along with Otezla and Pomalyst. Fourth-quarter results were disappointing but the company’s outlook for 2017 was encouraging. Shares of Celgene have outperformed the industry in the past one year. However, Celgene is highly dependent on Revlimid for growth. Stiff competition in target markets is another concern." (3/9/2017)
  • 3. Robert W. Baird analysts commented, "Celgene reported positive top-line data from the SUNBEAM trial of ozanimod in multiple sclerosis. Though no numbers were provided, it looks like the primary and key secondary endpoints were met, with a similar safety profile versus the Phase 2 studies. Though we find the lack of additional safety issues encouraging, success also depends on ability to compete with Gilenya, Tecfidera, and Roche's Ocrevus on efficacy. More complete data won't be available until later this half." (2/17/2017)
  • 4. Jefferies Group LLC analysts commented, "Though updates were mostly incremental given recent pre-reporting, the review of sales dynamics, 2017 guidance, and pipeline progress reaffirms our expectation for best-in-class medium-term growth from healthy core franchises. We expect continued strong execution throughout the year and lower-risk catalysts to drive appreciation towards levels reflecting underappreciated prospects of their products and portfolio." (1/27/2017)

Who are some of Celgene Corporation's key competitors?

Who are Celgene Corporation's key executives?

Celgene Corporation's management team includes the folowing people:

  • Robert J. Hugin, Executive Chairman of the Board
  • Scott A. Smith, President, Chief Operating Officer
  • Mark J. Alles, Chief Executive Officer, Director
  • Peter N. Kellogg, Chief Financial Officer, Executive Vice President
  • Terrie Curran, President, Global Inflammation & Immunology Franchise
  • Michael F. Pehl, President, Hematology & Oncology
  • Rupert J. Vessey, President - Research and Early Development
  • Gerald F. Masoudi, Executive Vice President, General Counsel and Corporate Secretary
  • Michael D. Casey, Lead Independent Director
  • Michael W. Bonney, Director

Who owns Celgene Corporation stock?

Celgene Corporation's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.87%), Vanguard Group Inc. (6.65%), State Street Corp (4.16%), Jennison Associates LLC (1.70%), FMR LLC (1.52%) and Bank of New York Mellon Corp (1.30%). Company insiders that own Celgene Corporation stock include Corp /De/ Celgene, Ernest Mario, Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Michael W Bonney, Richard W Barker, Robert J Hugin, Rupert Vessey and Thomas O Daniel. View Institutional Ownership Trends for Celgene Corporation.

Who sold Celgene Corporation stock? Who is selling Celgene Corporation stock?

Celgene Corporation's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Jennison Associates LLC, Winslow Capital Management LLC, Parametric Portfolio Associates LLC, Renaissance Technologies LLC, Janus Capital Management LLC, Marshall Wace LLP and TCW Group Inc.. Company insiders that have sold Celgene Corporation stock in the last year include Gilla Kaplan, James J Loughlin, Michael A Friedman, Michael D Casey, Richard W Barker, Robert J Hugin and Rupert Vessey. View Insider Buying and Selling for Celgene Corporation.

Who bought Celgene Corporation stock? Who is buying Celgene Corporation stock?

Celgene Corporation's stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Bank of Montreal Can, Investec Asset Management LTD, OppenheimerFunds Inc., Wellington Management Group LLP, Clearbridge Investments LLC and State Street Corp. Company insiders that have bought Celgene Corporation stock in the last two years include Corp /De/ Celgene and Michael W Bonney. View Insider Buying and Selling for Celgene Corporation.

How do I buy Celgene Corporation stock?

Shares of Celgene Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celgene Corporation's stock price today?

One share of Celgene Corporation stock can currently be purchased for approximately $132.83.


MarketBeat Community Rating for Celgene Corporation (NASDAQ CELG)
Community Ranking:  4.1 out of 5 (   )
Outperform Votes:  1,473 (Vote Outperform)
Underperform Votes:  335 (Vote Underperform)
Total Votes:  1,808
MarketBeat's community ratings are surveys of what our community members think about Celgene Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Celgene Corporation (NASDAQ:CELG) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 4 Hold Ratings, 20 Buy Ratings
Consensus Rating:Buy (Score: 2.76)
Consensus Price Target: $140.24 (5.58% upside)

Analysts' Ratings History for Celgene Corporation (NASDAQ:CELG)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/16/2017Leerink SwannUpgradeMarket Perform -> Outperform$94.42 -> $150.00MediumView Rating Details
6/14/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$148.00LowView Rating Details
6/7/2017CannReiterated RatingBuyLowView Rating Details
6/6/2017Canaccord GenuitySet Price TargetBuy$156.00LowView Rating Details
6/1/2017MizuhoBoost Price TargetBuy -> Buy$130.00 -> $134.00MediumView Rating Details
5/24/2017BTIG ResearchReiterated RatingBuy$138.00LowView Rating Details
5/24/2017J P Morgan Chase & CoReiterated RatingBuyLowView Rating Details
5/22/2017Cantor FitzgeraldSet Price TargetBuy$160.00LowView Rating Details
5/22/2017Credit Suisse GroupSet Price TargetBuy$148.00LowView Rating Details
5/23/2017BMO Capital MarketsReiterated RatingOutperform$152.00MediumView Rating Details
5/22/2017Robert W. BairdReiterated RatingOutperform$162.00LowView Rating Details
5/17/2017Goldman Sachs Group, Inc. (The)Reiterated RatingSell$93.00 -> $98.00LowView Rating Details
5/13/2017Jefferies Group LLCSet Price TargetBuy$154.00LowView Rating Details
5/5/2017ArgusDowngradeBuy -> Hold$123.91 -> $124.46MediumView Rating Details
4/23/2017Barclays PLCReiterated RatingEqual Weight$120.00 -> $125.00LowView Rating Details
3/8/2017Cowen and CompanyReiterated RatingOutperform$150.00LowView Rating Details
1/27/2017Morgan StanleyLower Price TargetEqual Weight$120.00 -> $117.00N/AView Rating Details
1/8/2017Evercore ISIReiterated RatingBuy$135.00N/AView Rating Details
12/4/2016Royal Bank Of CanadaReiterated RatingOutperformN/AView Rating Details
11/9/2016Standpoint ResearchDowngradeBuy -> HoldN/AView Rating Details
10/20/2016Stifel NicolausSet Price TargetBuy$138.00N/AView Rating Details
10/18/2016Piper Jaffray CompaniesReiterated RatingBuyN/AView Rating Details
9/29/2016Citigroup Inc.Boost Price TargetBuy$124.00 -> $127.00N/AView Rating Details
9/16/2016Bank of America CorporationReiterated RatingBuy$128.00N/AView Rating Details
7/6/2016JMP SecuritiesReiterated RatingBuy$152.00N/AView Rating Details
5/25/2016William BlairReiterated RatingOutperformN/AView Rating Details
4/28/2016Raymond James Financial, Inc.Reiterated RatingBuyN/AView Rating Details
4/28/2016SunTrust Banks, Inc.Reiterated RatingBuy$145.00 -> $147.00N/AView Rating Details
1/22/2016Wells Fargo & CompanyReiterated RatingOutperformN/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral -> NeutralN/AView Rating Details
7/25/2015NomuraReiterated RatingBuy$165.00 -> $167.00N/AView Rating Details
7/15/2015Deutsche Bank AGBoost Price TargetBuy$160.00 -> $175.00N/AView Rating Details
7/2/2015Sanford C. BernsteinReiterated RatingBuy$154.00N/AView Rating Details
(Data available from 6/22/2015 forward)

Earnings

Earnings History for Celgene Corporation (NASDAQ:CELG)
Earnings by Quarter for Celgene Corporation (NASDAQ:CELG)
Earnings History by Quarter for Celgene Corporation (NASDAQ CELG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/26/2017        
4/27/2017Q1 2017$1.47$1.68$3.04 billion$2.96 billionViewN/AView Earnings Details
1/26/2017Q416$1.59$1.61$3.03 billion$2.98 billionViewN/AView Earnings Details
10/27/2016Q316$1.31$1.58$2.84 billion$2.98 billionViewListenView Earnings Details
7/28/2016Q216$1.39$1.44$2.70 billion$2.74 billionViewListenView Earnings Details
4/28/2016Q116$1.29$1.32$2.59 billion$2.51 billionViewListenView Earnings Details
1/28/2016Q415$1.22$1.18$2.54 billion$2.54 billionViewListenView Earnings Details
11/5/2015Q315$1.09$1.23$2.40 billion$2.33 billionViewN/AView Earnings Details
7/23/2015Q215$1.08$1.23$2.24 billion$2.28 billionViewListenView Earnings Details
4/30/2015Q115$0.93$0.95$2.11 billion$2.08 billionViewN/AView Earnings Details
1/29/2015Q414$0.88$0.91$2.08 billion$2.09 billionViewN/AView Earnings Details
10/23/2014Q314$0.82$0.97$1.96 billion$1.96 billionViewListenView Earnings Details
7/24/2014Q214$0.77$0.80$1.85 billion$1.87 billionViewN/AView Earnings Details
4/24/2014Q114$1.65$1.67$1.77 billion$1.71 billionViewN/AView Earnings Details
1/30/2014Q413$1.54$1.51$1.72 billion$1.76 billionViewListenView Earnings Details
10/24/2013Q313$1.54$1.56$1.64 billion$1.67 billionViewN/AView Earnings Details
7/25/2013Q2 2013$1.44$1.52$1.54 billion$1.56 billionViewListenView Earnings Details
4/25/2013Q1 2013$1.35$1.37$1.47 billion$1.43 billionViewListenView Earnings Details
1/24/2013Q4 2012$1.31$1.32$1.45 billion$1.42 billionViewListenView Earnings Details
10/25/2012$1.26$1.29ViewN/AView Earnings Details
7/26/2012$1.19$1.22ViewN/AView Earnings Details
4/26/2012$1.13$1.08ViewN/AView Earnings Details
1/26/2012$1.06$1.05ViewN/AView Earnings Details
10/27/2011$0.95$1.02ViewN/AView Earnings Details
7/28/2011$0.85$0.89ViewN/AView Earnings Details
4/28/2011$0.80$0.83ViewN/AView Earnings Details
1/27/2011$0.73$0.73ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Celgene Corporation (NASDAQ:CELG)
2017 EPS Consensus Estimate: $6.68
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$1.44$1.46$1.45
Q2 20171$1.63$1.63$1.63
Q3 20171$1.77$1.77$1.77
Q4 20171$1.83$1.83$1.83
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Celgene Corporation (NASDAQ:CELG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Celgene Corporation (NASDAQ:CELG)
Insider Ownership Percentage: 0.95%
Institutional Ownership Percentage: 78.26%
Insider Trades by Quarter for Celgene Corporation (NASDAQ:CELG)
Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)
Insider Trades by Quarter for Celgene Corporation (NASDAQ:CELG)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/19/2017Michael D. CaseyDirectorSell9,250$125.59$1,161,707.50View SEC Filing  
6/15/2017Rupert VesseyInsiderSell4,785$120.18$575,061.30View SEC Filing  
5/1/2017James J LoughlinDirectorSell9,250$124.00$1,147,000.00View SEC Filing  
3/30/2017Gilla KaplanDirectorSell14,033$123.83$1,737,706.39View SEC Filing  
3/1/2017Rupert VesseyInsiderSell4,000$124.42$497,680.00View SEC Filing  
11/9/2016Michael A FriedmanDirectorSell18,600$116.10$2,159,460.00View SEC Filing  
10/24/2016Corp /De/ CelgeneMajor ShareholderBuy800,150$14.00$11,202,100.00View SEC Filing  
10/3/2016Michael A FriedmanDirectorSell56,116$103.66$5,816,984.56View SEC Filing  
9/23/2016Richard W BarkerDirectorSell20,000$110.82$2,216,400.00View SEC Filing  
9/15/2016Gilla KaplanDirectorSell9,710$106.44$1,033,532.40View SEC Filing  
8/23/2016James J LoughlinDirectorSell27,500$114.10$3,137,750.00View SEC Filing  
8/22/2016Michael D CaseyDirectorSell43,134$114.01$4,917,707.34View SEC Filing  
7/28/2016Robert J HuginInsiderSell100,000$110.00$11,000,000.00View SEC Filing  
6/20/2016Robert J HuginInsiderSell75,000$100.16$7,512,000.00View SEC Filing  
4/4/2016Gilla KaplanDirectorSell15,967$101.84$1,626,079.28View SEC Filing  
3/3/2016Michael W BonneyDirectorBuy2,000$103.01$206,020.00View SEC Filing  
2/22/2016James J LoughlinDirectorSell2,100$104.12$218,652.00View SEC Filing  
12/28/2015Ernest MarioDirectorSell40,000$119.36$4,774,400.00View SEC Filing  
12/23/2015Michael D CaseyDirectorSell20,000$122.11$2,442,200.00View SEC Filing  
12/21/2015Gilla KaplanDirectorSell14,464$110.62$1,600,007.68View SEC Filing  
9/10/2015Gilla KaplanDirectorSell15,000$122.45$1,836,750.00View SEC Filing  
9/8/2015Michael D. CaseyDirectorSell15,000$121.76$1,826,400.00View SEC Filing  
7/13/2015Thomas O DanielInsiderSell30,156$120.78$3,642,241.68View SEC Filing  
6/10/2015Gilla KaplanDirectorSell15,000$111.74$1,676,100.00View SEC Filing  
6/9/2015Michael D CaseyDirectorSell15,000$111.18$1,667,700.00View SEC Filing  
2/26/2015Gilla KaplanDirectorSell15,000$122.89$1,843,350.00View SEC Filing  
2/6/2015Mark J AllesInsiderSell117,099$120.68$14,131,507.32View SEC Filing  
1/15/2015Lawrence V SteinInsiderSell26,666$120.01$3,200,186.66View SEC Filing  
1/2/2015Gilla KaplanDirectorSell45,536$113.47$5,166,969.92View SEC Filing  
12/8/2014Gilla KaplanDirectorSell15,000$118.20$1,773,000.00View SEC Filing  
11/3/2014Robert J HuginInsiderSell158,000$106.68$16,855,440.00View SEC Filing  
10/27/2014Ernest MarioDirectorSell100,000$102.85$10,285,000.00View SEC Filing  
10/24/2014Michael D CaseyDirectorSell15,000$102.94$1,544,100.00View SEC Filing  
9/8/2014Gilla KaplanDirectorSell30,000$93.73$2,811,900.00View SEC Filing  
8/4/2014Perry A KarsenInsiderSell39,104$87.55$3,423,555.20View SEC Filing  
7/25/2014Richard W BarkerDirectorSell17,600$87.03$1,531,728.00View SEC Filing  
5/1/2014Perry KarsenInsiderSell11,922$146.78$1,749,911.16View SEC Filing  
3/4/2014Michael CaseyDirectorSell12,770$162.33$2,072,954.10View SEC Filing  
2/5/2014Ernest MarioDirectorSell13,500$151.87$2,050,245.00View SEC Filing  
12/23/2013Lawrence SteinInsiderSell12,062$168.19$2,028,707.78View SEC Filing  
10/25/2013Carrie Smith CoxDirectorSell18,750$157.67$2,956,312.50View SEC Filing  
9/4/2013Gilla KaplanDirectorSell15,000$143.92$2,158,800.00View SEC Filing  
8/28/2013Thomas DanielInsiderSell32,263$137.06$4,421,966.78View SEC Filing  
8/2/2013Perry A KarsenInsiderSell93,008$146.50$13,625,672.00View SEC Filing  
5/30/2013Robert J HuginInsiderSell68,087$123.58$8,414,191.46View SEC Filing  
5/29/2013Ernest MarioDirectorBuy1,000$123.72$123,720.00View SEC Filing  
5/28/2013Thomas O DanielInsiderSell32,959$124.91$4,116,908.69View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Celgene Corporation (NASDAQ:CELG)
Latest Headlines for Celgene Corporation (NASDAQ:CELG)
Source:
DateHeadline
businesswire.com logoCelebrated Photographer Martin Schoeller Shines a Light on People With Psoriatic Disease Including Olympic Swimmer and Author Dara Torres as Part of Celgene’s SHOW MORE OF ...
www.businesswire.com - June 22 at 11:16 AM
rttnews.com logoCelgene Corp. (CELG) Climbed To A New High For The Year
www.rttnews.com - June 22 at 11:16 AM
finance.yahoo.com logoTechnician: Forget tech, keep buying health-care stocks
finance.yahoo.com - June 22 at 11:16 AM
finance.yahoo.com logoFinding real growth in a split market
finance.yahoo.com - June 22 at 11:16 AM
finance.yahoo.com logoCramer finds where the real growth is in a split market
finance.yahoo.com - June 22 at 11:16 AM
finance.yahoo.com logoWhat Analysts Recommend for Celgene in 2017
finance.yahoo.com - June 22 at 11:16 AM
finance.yahoo.com logoCelebrated Photographer Martin Schoeller Shines a Light on People With Psoriatic Disease Including Olympic Swimmer and Author Dara Torres as Part of Celgene’s SHOW MORE OF YOU Campaign
finance.yahoo.com - June 22 at 11:16 AM
finance.yahoo.com logoOtezla Could Significantly Drive Celgene’s Revenue Growth
finance.yahoo.com - June 22 at 11:16 AM
americanbankingnews.com logoCelgene Corporation (CELG) Upgraded to Hold at BidaskClub
www.americanbankingnews.com - June 21 at 8:18 PM
finance.yahoo.com logoCelgene Heading for All-Time High
finance.yahoo.com - June 21 at 5:22 PM
americanbankingnews.com logoCelgene Corporation Target of Unusually High Options Trading (CELG)
www.americanbankingnews.com - June 21 at 1:28 PM
americanbankingnews.com logoCelgene Corporation (CELG) Expected to Post Quarterly Sales of $3.23 Billion
www.americanbankingnews.com - June 21 at 10:45 AM
americanbankingnews.com logoMichael D. Casey Sells 9,250 Shares of Celgene Corporation (CELG) Stock
www.americanbankingnews.com - June 20 at 7:37 PM
finance.yahoo.com logoHow Did Celgene Perform in 1Q17?
finance.yahoo.com - June 20 at 4:52 PM
finance.yahoo.com logoNasdaq Falls, Dow Holds Up; Biotechs On Fire As Oil Slumps Again
finance.yahoo.com - June 20 at 4:52 PM
finance.yahoo.com logoBiotech Stock With 50% Profit Margin Nears Buy Zone
finance.yahoo.com - June 20 at 4:52 PM
finance.yahoo.com logoRevlimid Could Continue to Drive Celgene’s Revenue Growth in 2017
finance.yahoo.com - June 20 at 4:52 PM
finance.yahoo.com logoCelgene Announces Clinical Data Evaluating Broad Range of Blood Cancers to Be Presented at EHA 2017
finance.yahoo.com - June 20 at 12:29 AM
finance.yahoo.com logoCelgene Presents Interim Results from Cancer Drug Study
finance.yahoo.com - June 20 at 12:29 AM
businesswire.com logoCelgene Announces Clinical Data Evaluating Broad Range of Blood ... - Business Wire (press release)
www.businesswire.com - June 19 at 2:26 PM
businesswire.com logoMetaStat Announces Completion of Second Milestone of its Pilot ... - Business Wire (press release)
www.businesswire.com - June 19 at 2:26 PM
americanbankingnews.com logoCelgene Corporation (CELG) Expected to Announce Earnings of $1.61 Per Share
www.americanbankingnews.com - June 19 at 10:26 AM
seekingalpha.com logoCelgene outperforms after upgrade - Seeking Alpha
seekingalpha.com - June 18 at 11:08 AM
finance.yahoo.com logo3 Top Healthcare Stocks You Haven't Thought Of
finance.yahoo.com - June 18 at 11:08 AM
finance.yahoo.com logoUpdated Data from Phase IIIb MAGNIFY Study of REVLIMID (lenalidomide) and Rituximab Combination (R2) Show Clinical Activity and Responses in Relapsed/Refractory Follicular and Marginal Zone Lymphoma
finance.yahoo.com - June 17 at 4:30 PM
americanbankingnews.com logoCelgene Corporation (CELG) Insider Sells $575,061.30 in Stock
www.americanbankingnews.com - June 16 at 7:34 PM
finance.yahoo.com logoMorning Movers: Celgene Gains, Nike Drops, Valeant Rises
finance.yahoo.com - June 16 at 4:57 PM
finance.yahoo.com logoWhy Celgene is Bucking Biotech Weakness Today
finance.yahoo.com - June 16 at 4:57 PM
finance.yahoo.com logoCelgene Corp. – Value Analysis (NASDAQ:CELG) : June 16, 2017
finance.yahoo.com - June 16 at 4:57 PM
finance.yahoo.com logoCelgene's Future Is Tied To One 'Mixer' Drug — And That's OK
finance.yahoo.com - June 16 at 4:57 PM
fool.com logo2 Incredibly Cheap Biotech Stocks
www.fool.com - June 16 at 1:05 PM
americanbankingnews.com logoStock Traders Purchase Large Volume of Celgene Corporation Call Options (CELG)
www.americanbankingnews.com - June 16 at 12:04 PM
americanbankingnews.com logoCelgene Corporation (CELG) Lifted to Outperform at Leerink Swann
www.americanbankingnews.com - June 16 at 8:22 AM
americanbankingnews.com logoOppenheimer Holdings, Inc. Analysts Give Celgene Corporation (CELG) a $148.00 Price Target
www.americanbankingnews.com - June 15 at 10:46 PM
finance.yahoo.com logoCelgene Corp. breached its 50 day moving average in a Bullish Manner : CELG-US : June 15, 2017
finance.yahoo.com - June 15 at 6:02 PM
finance.yahoo.com logoCould This Small Biotech Pique Interest Of Gilead And Others?
finance.yahoo.com - June 15 at 6:02 PM
fool.com logoCan Celgene Corporation Be a Value Stock?
www.fool.com - June 15 at 9:37 AM
americanbankingnews.com logoCelgene Co. (CELG) Upgraded by BidaskClub to "Sell"
www.americanbankingnews.com - June 14 at 10:58 PM
reuters.com logoBRIEF-Celgene International Sàrl announces results from phase 2a SLE-001 trial evaluating CC-220
www.reuters.com - June 14 at 10:01 PM
seekingalpha.com logoA Threat To Merck & Co's Lead In Multiple Myeloma - Seeking Alpha
seekingalpha.com - June 14 at 5:01 PM
finance.yahoo.com logoPhase 2a Safety and Efficacy Data Support Further Development of Oral CC-220 in Patients with Lupus
finance.yahoo.com - June 14 at 5:01 PM
feeds.benzinga.com logobiOasis CEO Dr. Mark Day Releases Details of Corporate Plans in Message to Shareholders
feeds.benzinga.com - June 13 at 11:16 PM
finance.yahoo.com logo[$$] Dragonfly Therapeutics Strikes Immuno-Oncology Deal With Celgene
finance.yahoo.com - June 13 at 8:52 PM
fool.com logoCelgene's Next Blockbuster: What You Need to Know
www.fool.com - June 13 at 8:28 AM
prnewswire.com logoDragonfly Therapeutics Announces Strategic Collaboration with Celgene to ...
www.prnewswire.com - June 12 at 5:14 PM
finance.yahoo.com logoWaltham-based Dragonfly inks collaboration with Celgene, bags $33M
finance.yahoo.com - June 12 at 5:14 PM
americanbankingnews.com logoCelgene Co. (CELG) Given a $148.00 Price Target at Oppenheimer Holdings Inc.
www.americanbankingnews.com - June 11 at 7:52 AM
investorplace.com logoCelgene Corporation (CELG) Stock’s Range Is Tight — Time to Profit
investorplace.com - June 9 at 11:40 AM
americanbankingnews.com logoCelgene Co. (CELG) Receives Buy Rating from Cann
www.americanbankingnews.com - June 7 at 9:44 PM
finance.yahoo.com logoWhy bluebird bio Inc. Flew Higher Again Today
finance.yahoo.com - June 7 at 8:33 PM

Social

Chart

Celgene Corporation (CELG) Chart for Thursday, June, 22, 2017

This page was last updated on 6/22/2017 by MarketBeat.com Staff